Nature. 2011 Jan 27;469(7331):483-90.

The challenge of new drug discovery for tuberculosis.

Koul A, Arnoult E, Lounis N, Guillemont J, Andries K.

Source

Department of Antimicrobial Research, Janssen Research and Development, Johnson & Johnson, Turnhoutseweg 30, B-2340 Beerse, Belgium. akoul@its.jnj.com

Abstract

Tuberculosis (TB) is more prevalent in the world today than at any other time in human history. Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse strategies to survive in a variety of host lesions and to evade immune surveillance. A key question is how robust are our approaches to discovering new TB drugs, and what measures could be taken to reduce the long and protracted clinical development of new drugs. The emergence of multi-drug-resistant strains of M. tuberculosis makes the discovery of new molecular scaffolds a priority, and the current situation even necessitates the re-engineering and repositioning of some old drug families to achieve effective control. Whatever the strategy used, success will depend largely on our proper understanding of the complex interactions between the pathogen and its human host. In this review, we discuss innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients.

PMID:: 21270886; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

Antitubercular Agents

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Tuberculosis - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

[Frontier of mycobacterium research--host vs. mycobacterium]. [Kekkaku. 2005]
[Frontier of mycobacterium research--host vs. mycobacterium].
Okada M, Shirakawa T. Kekkaku. 2005 Sep; 80(9):613-29.
Review [Development of antituberculous drugs: current status and future prospects]. [Kekkaku. 2006]
Review [Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Kekkaku. 2006 Dec; 81(12):753-74.
[Recent progress in mycobacteriology]. [Kekkaku. 2007]
[Recent progress in mycobacteriology].
Okada M, Kobayashi K. Kekkaku. 2007 Oct; 82(10):783-99.
Review The resumption of consumption -- a review on tuberculosis. [Mem Inst Oswaldo Cruz. 2006]
Review The resumption of consumption -- a review on tuberculosis.
Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. Mem Inst Oswaldo Cruz. 2006 Nov; 101(7):697-714.
Review New tuberculosis drugs on the horizon. [Curr Opin Microbiol. 2011]
Review New tuberculosis drugs on the horizon.
Cole ST, Riccardi G. Curr Opin Microbiol. 2011 Oct; 14(5):570-6. Epub 2011 Aug 5.

See reviews... See all...

Cited by 10 PubMed Central articles

Nitazoxanide Stimulates Autophagy and Inhibits mTORC1 Signaling and Intracellular Proliferation of Mycobacterium tuberculosis. [PLoS Pathog. 2012]
Nitazoxanide Stimulates Autophagy and Inhibits mTORC1 Signaling and Intracellular Proliferation of Mycobacterium tuberculosis.
Lam KK, Zheng X, Forestieri R, Balgi AD, Nodwell M, Vollett S, Anderson HJ, Andersen RJ, Av-Gay Y, Roberge M. PLoS Pathog. 2012 May; 8(5):e1002691. Epub 2012 May 10.
Antimycobacterial Activities of Novel 5-(1H-1,2,3-Triazolyl)Methyl Oxazolidinones. [Tuberc Res Treat. 2012]
Antimycobacterial Activities of Novel 5-(1H-1,2,3-Triazolyl)Methyl Oxazolidinones.
Phillips OA, Udo EE, Varghese R. Tuberc Res Treat. 2012; 2012:289136. Epub 2012 Apr 11.
Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium tuberculosis. [ACS Med Chem Lett. 2011]
Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium tuberculosis.
de Carvalho LP, Darby CM, Rhee KY, Nathan C. ACS Med Chem Lett. 2011; 2(11):849-854.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The challenge of new drug discovery for tuberculosis.
The challenge of new drug discovery for tuberculosis.
Nature. 2011 Jan 27 ;469(7331):483-90.

PubMed
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort.
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort.
Genes Immun. 2011 Jun ;12(4):270-9. Epub 2011 Jan 27 .

PubMed
RANK is expressed in metastatic melanoma and highly upregulated on melanoma-init...
RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells.
J Invest Dermatol. 2011 Apr ;131(4):944-55. Epub 2011 Jan 27 .

PubMed
Hyperoxia impairs alveolar formation and induces senescence through decreased hi...
Hyperoxia impairs alveolar formation and induces senescence through decreased histone deacetylase activity and up-regulation of p21 in neonatal mouse lung.
Pediatr Res. 2011 May ;69(5 Pt 1):371-7.

PubMed
Changes to perceptions of the pros and cons of genetic susceptibility testing af...
Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk.
Genet Med. 2011 May ;13(5):409-14.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: